Annex I
United Kingdom
Pursuant to paragraph 3 of Decision XII/2 of the 12th Meeting of the Parties to the Montreal Protocol on measures to facilitate the transition to chlorofluorocarbon-free metered-dose inhalers (MDIs), the following Parties have determined that, due to the presence of suitable non-CFC MDIs, CFCs no longer qualify as ‘essential’ under the Protocol when combined with following products:
| Source: www.unep.org/ozone/dec12-2-3.pdf | |||||||||||||||||||
| ProductCountry | Salbutamol | Terbutaline | Fenoterol | Orciprenaline | Reproterol | Carbuterol | Hexoprenaline | Pirbuterol | Clenbuterol | Bitolterol | Procaterol | Beclomethasone | Dexamethasone | Fluinisolide | Fluiticasone | Budesonide | Triamcinolone | Ipratropium bromide | Oxitropium Bromide |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Austria | X | X | X | X | X | X | X | X | X | X | X | ||||||||
| Belgium | X | X | X | X | X | X | X | X | X | X | X | ||||||||
| Czech Republic | X | X | X | X | X | X | X | X | X | X | X | ||||||||
| Denmark | X | X | X | X | X | X | X | X | X | X | X | ||||||||
| Finland | X | ||||||||||||||||||
| France | X | ||||||||||||||||||
| Germany | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X |
| Greece | X | X | X | X | X | X | X | X | X | X | X | ||||||||
| Ireland | X | ||||||||||||||||||
| Luxembourg | X | ||||||||||||||||||
| Portugal | X | X | X | X | X | X | X | X | X | X | X | ||||||||
| The Netherlands | X | X | X | X | X | X | X | X | X | X | X | ||||||||
| Norway | X | X | X | X | X | X | X | X | X | X | X | ||||||||
| Sweden | X | ||||||||||||||||||
| UK | X | ||||||||||||||||||